Close Menu
October 14, 2020
Sponsored by
Inivata

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

GenomeWebinar

Lower Gastrointestinal Medical Oncology and Trials Lead,
Peter MacCallum Cancer Centre

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials. Those with low-risk disease may be able to avoid chemotherapy and its associated side effects.

Methods for ctDNA detection require very high-sensitivity approaches in order to detect microscopic disease after surgery or treatment. Methods have been developed that utilize genomic profiling of tumor tissue based on patient-specific next-generation sequencing (NGS) panels. High-sensitivity personalized panels allow detection of residual disease and serial monitoring for detection of recurrence.

This webinar will discuss the use of such panels to test for residual disease and recurrence in the treatment of colorectal cancer.

Sponsored by

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.